Venture Certified
| 혁신성장유형 | 2021-11-24 ~ 2024-11-23 | 20211125030126 | 2021-11-24 |
| 혁신성장유형 | 2024-11-24 ~ 2027-11-23 | 20250204030086 | 2021-11-24 |
Revenue CAGR -35.5%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 2.0B | 4.1B | 4.9B |
| Operating Profit | -1.4B | -0.8B | -1.7B |
| Net Profit | -1.2B | -0.5B | -1.5B |
| Total Assets | 17.3B | 2.4B | 2.8B |
| Total Liabilities | 1.0B | 0.4B | 0.3B |
| Total Equity | 16.4B | 2.0B | 2.5B |
Operating Loss: Op. profit -1B
Revenue down 51% YoY
3 Consecutive Years of Net Loss
▼ 55.1%
▼ 13.5%
▼ 159.1%
▼ 63.5%
▲ 82.7%
| Name | Position | Role |
|---|---|---|
| 김은영 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "대전 유성구",
"ceo_name": "김은영",
"certificate": [
{
"cert_number": "20211125030126",
"changes": "",
"disclosure_date": "2021-11-25",
"first_cert_date": "2021-11-24",
"no": "1",
"type": "혁신성장유형",
"valid_period": "2021-11-24 ~ 2024-11-23"
},
{
"cert_number": "20250204030086",
"changes": "",
"disclosure_date": "2025-02-04",
"first_cert_date": "2021-11-24",
"no": "2",
"type": "혁신성장유형",
"valid_period": "2024-11-24 ~ 2027-11-23"
}
],
"company_name": "주식회사 사이키바이오텍",
"corp_no": "160111-*******",
"financials": {
"2022": {
"capital_stock": 222221000,
"cost_of_sales": 387056000,
"current_assets": 197145000,
"current_liabilities": 33414000,
"gross_profit": 98867000,
"net_income": -146708000,
"net_income_bs": -146708000,
"non_current_assets": 83812000,
"non_current_liabilities": 0,
"non_operating_expenses": 0,
"non_operating_income": 25134000,
"operating_profit": -171842000,
"revenue": 485923000,
"sga_expenses": 270709000,
"total_assets": 280957000,
"total_equity": 247543000,
"total_liabilities": 33414000
},
"2023": {
"capital_stock": 222221000,
"cost_of_sales": 228441000,
"current_assets": 172781000,
"current_liabilities": 39974000,
"gross_profit": 184853000,
"net_income": -46812000,
"net_income_bs": -46812000,
"non_current_assets": 67924000,
"non_current_liabilities": 0,
"non_operating_expenses": 0,
"non_operating_income": 30761000,
"operating_profit": -77573000,
"revenue": 413294000,
"sga_expenses": 262426000,
"total_assets": 240705000,
"total_equity": 200731000,
"total_liabilities": 39974000
},
"2024": {
"capital_stock": 257775000,
"cost_of_sales": 109835000,
"current_assets": 1582150000,
"current_liabilities": 39907000,
"gross_profit": 92061000,
"net_income": -116520000,
"net_income_bs": -116520000,
"non_current_assets": 152672000,
"non_current_liabilities": 59676000,
"non_operating_expenses": 5454000,
"non_operating_income": 30531000,
"operating_profit": -141597000,
"revenue": 201896000,
"sga_expenses": 233658000,
"total_assets": 1734822000,
"total_equity": 1635239000,
"total_liabilities": 99583000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "압타머 발굴 원천기술/치료제",
"phone": "042-936-****",
"years": [
2024,
2023,
2022
]
}